170 related articles for article (PubMed ID: 29245989)
1. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.
Kosovec JE; Zaidi AH; Omstead AN; Matsui D; Biedka MJ; Cox EJ; Campbell PT; Biederman RWW; Kelly RJ; Jobe BA
Oncotarget; 2017 Nov; 8(59):100421-100432. PubMed ID: 29245989
[TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Zaidi AH; Kosovec JE; Matsui D; Omstead AN; Raj M; Rao RR; Biederman RWW; Finley GG; Landreneau RJ; Kelly RJ; Jobe BA
Ann Surg; 2017 Jul; 266(1):91-98. PubMed ID: 27471841
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
[TBL] [Abstract][Full Text] [Related]
4. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.
Malhotra U; Zaidi AH; Kosovec JE; Kasi PM; Komatsu Y; Rotoloni CL; Davison JM; R C; Irvin ; Hoppo T; Nason KS; Kelly LA; Gibson MK; Jobe BA
PLoS One; 2013; 8(11):e78343. PubMed ID: 24223792
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Torres-Guzmán R; Calsina B; Hermoso A; Baquero C; Alvarez B; Amat J; McNulty AM; Gong X; Boehnke K; Du J; de Dios A; Beckmann RP; Buchanan S; Lallena MJ
Oncotarget; 2017 Sep; 8(41):69493-69507. PubMed ID: 29050219
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
Wang D; Bao H
Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
[TBL] [Abstract][Full Text] [Related]
11. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
12. A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
Hassan MS; Awasthi N; Li J; Schwarz MA; Schwarz RE; von Holzen U
PLoS One; 2017; 12(2):e0171824. PubMed ID: 28225784
[TBL] [Abstract][Full Text] [Related]
13. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
14. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract][Full Text] [Related]
15. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.
Zaidi AH; Kelly RJ; Gorbunova A; Omstead AN; Salvitti MS; Zheng P; Kosovec JE; Lee S; Ayazi S; Babar L; Finley GG; Goel A; Jobe BA
Oncotarget; 2021 Feb; 12(4):292-303. PubMed ID: 33659041
[TBL] [Abstract][Full Text] [Related]
17. The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models.
Hu W; Wang L; Luo J; Zhang J; Li N
Breast Cancer (Dove Med Press); 2023; 15():899-912. PubMed ID: 38090281
[TBL] [Abstract][Full Text] [Related]
18. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
19. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T; Schultz CW; Jain A; Brown SZ; Haber A; Goetz A; Xi C; Su GH; Xu L; Posey J; Jiang W; Yeo CJ; Golan T; Pishvaian MJ; Brody JR
Mol Cancer Res; 2019 Oct; 17(10):2029-2041. PubMed ID: 31383722
[TBL] [Abstract][Full Text] [Related]
20. Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Gergen AK; Kohtz PD; Halpern AL; White AM; Meng X; Fullerton DA; Weyant MJ
J Surg Res; 2021 Apr; 260():436-447. PubMed ID: 33272595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
